According to Report Study, the global dengue vaccines market size is expected to hit US$ 1.3 billion by 2030 from valued US$ 0.4 Bn in 2020, expanding growth at a CAGR of 11.2% from 2021 to 2030.
According to Report Study, the global dengue vaccines market size is expected to hit US$ 1.3 billion by 2030 from valued US$ 0.4 Bn in 2020, expanding growth at a CAGR of 11.2% from 2021 to 2030.
Dengue is a mosquito-borne tropical disease caused by dengue virus. Symptoms usually begin three to 14 days after infection. These include high fever, vomiting, headache, muscle & joint pain, and a characteristic skin rash. A vaccine to prevent dengue (Dengvaxia) has been licensed, and is available in some countries for people aged between nine and 45 years. The World Health Organization recommends that the vaccine should only be given to persons with confirmed prior history of dengue virus infection. The vaccine manufacturer, Sanofi Pasteur, announced in 2017 that people who receive the vaccine and have not previously infected by the virus could be at risk of developing severe dengue, if they are infected after being vaccinated.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38197
Disrupted sanitation services and curtailed water supply lead to conditions that assist mosquito breeding and proliferation, while warm temperatures lead to longer active season for mosquitos. Climate change is likely to increase the burden of dengue, which, in turn, is anticipated to boost the growth of the global dengue vaccines market.
The market in Asia Pacific is expected to expand at a high CAGR from 2021 to 2030, owing to highly developed healthcare sector, rise in prevalence of dengue, and continuous evolution of dengue vaccines. The region offers significant opportunities in the dengue vaccines market.
R&D Becomes Deciding Factor for Greater Acceptability of Dengue Vaccines
The commitment to R&D for vaccine development is emerging as one of the most crucial strategies to gain a competitive edge in the dengue vaccines market. Continuous research holds promising potentials for the development of next-gen dengue, malaria, and tuberculosis vaccines. The R&D has become the need of the hour, since greater acceptability, improved production, and cost effectiveness of dengue vaccines are key deciding factors for its success in the market landscape.
The Developing Countries Vaccine Manufacturers Network (DCVMN) is gaining popularity for its growing capacity and willingness to effectively advance vaccine clinical development. Network members linked with the dengue vaccines market are boosting their production capacities to combat high incidence of dengue and other regional infectious diseases in patients.
Scope of The Report
| Report Coverage | Details |
| Market Size By 2030 | USD 1.3 Billion |
| CAGR from 2022 to 2030 | 11.2% |
| Largest Market | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2021 |
| Forecast Data | 2022 to 2030 |
| Key Players | Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck Co. & Inc., GlaxoSmithKline plc, GeneOne Life Science, Medigen Vaccine Biologics, Panacea Biotec Limited and Others. |
Access to Safe, Effective Dengue Vaccine Candidates Benefits Endemic Countries
According to the World Health Organization (WHO), dengue represents one of the 10 biggest global health threats. Panacea Biotec - a global generic and specialty pharmaceutical and vaccine maker registered in India has announced the successful completion of phase I/II study of its novel tetravalent recombinant chimeric dengue candidate vaccine DengiAll. Companies in the dengue vaccines market are taking cues from such news, and making efforts to increase access to safe and effective dengue vaccine candidates to minimize the devastating impact of dengue fever in endemic countries such as Colombia, Sri Lanka, and Argentina.
Companies in the dengue vaccines market are innovating in vaccine candidates that induce robust, balanced, and neutralizing antibody response against all four dengue virus serotypes.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38197
Report Highlights
In terms of category, the live attenuated vaccines segment accounted for 33% share of the global market in 2020. The segment is anticipated to expand at a CAGR of 9.8% from 2021 to 2030.
In terms of product, the global dengue vaccines market has been bifurcated into CYD-TDV (Dengvaxia) and others. The CYD-TDV (Dengvaxia) segment accounted for 97.60% share of the market in 2020. The segment is likely to expand at a CAGR of 10.80% from 2021 to 2030.
Based on route of administration, the global dengue vaccines market has been classified into subcutaneous and others. The subcutaneous segment accounted for 75.50% share of the market in 2020. The segment is projected to expand at a CAGR of 11.2% from 2021 to 2031. Dengvaxia is given by the doctor or nurse as an injection underneath the skin (subcutaneous route) in the upper arm. Adults or children will receive three injections of 0.5 mL each at 6-month intervals. Currently, Dengvaxia is the only approved drug for dengue, which is used in dengue treatment.
In terms of end user, the global dengue vaccines market has been divided into hospitals, government institutes, specialty clinics, and others. The hospitals segment dominated the global market in 2020. The segment is anticipated to reach US$ 1.1 Bn by 2030.
In terms of region, the Asia Pacific dominated the global dengue vaccines market in 2020, followed by Latin America. Asia Pacific’s significant market share can be ascribed to presence of a large number of key players, rise in prevalence of dengue, improving healthcare infrastructure, and funding from governments and large corporates. Brazil and Mexico are the leading markets in the region, due to the rise in investment in development of well-equipped health care institutions and rise in prevalence of dengue cases.
Competitive Landscape
This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2017 to 2019.
The analysts have provided a comprehensive analysis of the competitive landscape of the global dengue vaccines market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation expected to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users) and other segments.
- Company Overview
- Company Market Share/Positioning Analysis
- Product Offerings
- Financial Performance
- Recent Initiatives
- Key Strategies Adopted by Players
- Vendor Landscape
- List of Suppliers
- List of Buyers
The global dengue vaccines market is fragmented in terms of number of players. Key players operating in the global market include Sanofi Pasteur Limited, Takeda Pharmaceutical Company Limited, Merck Co. & Inc., GlaxoSmithKline plc, GeneOne Life Science, Medigen Vaccine Biologics, Panacea Biotec Limited, Sun Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Biological E, and VabioTech.
Market Segmentation
By Category
-
- Live Attenuated Vaccines
- Chimeric Live Attenuated Vaccines
- Others
By Product
-
- CYD-TDV (Dengvaxia)
- Others
By Route of Administration
-
- Subcutaneous
- Others
By End User
-
- Hospitals
- Government Institutes
- Specialty Clinics
- Others
By Region
-
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38197
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333